BEDFORD, Mass. & CAMBRIDGE, Mass.– Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company focused on restoring protein expression through RNA medicines, and Biogen Inc. (Nasdaq: BIIB) today announced the presentation of new clinical data on zorevunersen at the 36th International Epilepsy Congress (IEC), being held August 30 – September 3, 2025 in Lisbon, Portugal.
Zorevunersen, an investigational antisense oligonucleotide, is being studied as a potential disease-modifying treatment for Dravet syndrome in the global Phase 3 EMPEROR trial.
Three-year results from open-label extension studies showed durable seizure reductions and sustained improvements in cognition and behavior on top of standard anti-seizure medicines. Patients also experienced meaningful reductions in overall seizure burden and increases in seizure-free days with ongoing treatment.
“With these additional clinical data, we are developing a long-term understanding of the potential for zorevunersen to improve outcomes for patients by addressing the underlying genetic cause of Dravet syndrome,” said Barry Ticho, M.D., Ph.D., Chief Medical Officer of Stoke Therapeutics. “The substantial and durable reductions in seizures and improvements in cognition and behavior in patients already receiving standard anti-seizure medicines support the potential for disease modification. We look forward to sharing and discussing our latest zorevunersen data, including new analyses related to improvements in seizure free days and quality of life, with the world’s leading epilepsy experts at this premier congress.”
“The zorevunersen data generated to date are encouraging and support the design of the Phase 3 EMPEROR study now enrolling and dosing patients,” said Katherine Dawson, M.D., Head of the Therapeutics Development Unit at Biogen. “The effects observed so far are bringing greater awareness to Dravet syndrome as a neurodevelopmental disorder while generating increasing interest in EMPEROR.”
